Compare Hard to Treat Diseases (HTDS) vs. Competitors

14 Followers

Comparison Results

HTDS

Hard to Treat Diseases

<$0.01

$5.48K

―

Scinai Immunotherapeutics

$2.87

$689.73K

―

-92.58%

―

PainReform

$0.99

$2.61M

-0.08

-88.41%

―

MSP Recovery

$0.01

$14.00

―

-99.64%

―

NewcelX

$3.35

$16.74M

8.86

-83.32%

1 Buy

0 Hold

0 Sell

Moderate Buy

Virax Biolabs Group Ltd. Class A

$2.91

$2.68M

-0.08

-88.33%

―

xxxxxxxxxxxxx

HTDS vs VRAX

xxxxxxxxxxxxx

Performance Comparison

HTDS

Hard to Treat Diseases

―

SCNI

Scinai Immunotherapeutics

1.21

-12.49

-91.17%

PRFX

PainReform

0.86

-5.67

-86.85%

MSPR

MSP Recovery

0.01

-1.14

-99.13%

NCEL

NewcelX

3.11

-14.49

-82.33%

VRAX

Virax Biolabs Group Ltd. Class A

1.99

-14.32

-87.80%

Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts

Compare More Stocks >